/SGHT
SGHT Stock - Sight Sciences, Inc.
Healthcare|Medical - DevicesNASDAQ
$6.83-7.83%
$0.58 (-7.83%) • Jan 13
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.23
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+39.1%upside
Target: $9.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SGHT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.76 – $6.90
TARGET (TP)$9.50
STOP LOSS$6.28
RISK/REWARD1:4.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.41
52W High$9.24
52W Low$2.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $79.87M | $81.06M | $71.33M | $48.96M | $27.64M |
| Gross Profit | $68.28M | $69.17M | $58.97M | $40.35M | $18.43M |
| Gross Margin | 85.5% | 85.3% | 82.7% | 82.4% | 66.7% |
| Operating Income | $-50,532,000 | $-57,274,000 | $-83,954,000 | $-51,478,000 | $-32,188,000 |
| Net Income | $-51,507,000 | $-55,547,000 | $-86,242,000 | $-62,960,000 | $-34,693,000 |
| Net Margin | -64.5% | -68.5% | -120.9% | -128.6% | -125.5% |
| EPS | $-1.03 | $-1.14 | $-1.80 | $-1.33 | $-0.74 |
Company Overview
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SGHTBeat Rate
67%
Last 18 quarters
Avg Surprise
+1.4%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+37.1%
$-0.22vs$-0.35
Q2 24
-13.8%
$-0.33vs$-0.29
Q3 24
+19.4%
$-0.25vs$-0.31
Q4 24
+4.3%
$-0.22vs$-0.23
Q1 25
-4.5%
$-0.23vs$-0.22
Q2 25
+3.4%
$-0.28vs$-0.29
Q3 25
+8.0%
$-0.23vs$-0.25
Q4 25
+38.5%
$-0.16vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.26 | $-0.16 | +38.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.35 | $-0.22 | +37.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.47 | $-0.46 | +2.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.46 | $-0.50 | -8.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.41 | $-0.49 | -19.5% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.93 | $-1.83 | -96.8% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about SGHT
What is SGHT's current stock price?
Sight Sciences, Inc. (SGHT) is currently trading at $6.83 per share. The stock has moved -7.83% today.
What is the analyst price target for SGHT?
The average analyst price target for SGHT is $9.50, based on 1 analyst.
What sector is Sight Sciences, Inc. in?
Sight Sciences, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is SGHT's market cap?
Sight Sciences, Inc. has a market capitalization of $0.36 billion, making it a small-cap company.
Does SGHT pay dividends?
No, Sight Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERS
Cerus Corporation
$2.52
Mkt Cap: $0.5B
CVRX
CVRx, Inc.
$6.11
Mkt Cap: $0.2B
LFCR
Lifecore Biomedical, Inc.
$7.46
Mkt Cap: $0.3B
MASS
908 Devices Inc.
$5.37
Mkt Cap: $0.2B
OMI
Owens & Minor, Inc.
$2.68
Mkt Cap: $0.2B
PRQR
ProQR Therapeutics N.V.
$1.64
Mkt Cap: $0.2B
QTRX
Quanterix Corporation
$7.16
Mkt Cap: $0.3B
SENS
Senseonics Holdings, Inc.
$7.13
Mkt Cap: $0.3B
SNWV
SANUWAVE Health, Inc.
$28.57
Mkt Cap: $0.2B
VMD
Viemed Healthcare, Inc.
$7.25
Mkt Cap: $0.3B
Explore stocks similar to SGHT for comparison